KDM5A and non-small cell lung carcinoma: In EGFR-mutant non-small cell lung cancer (NSCLC) cells treated with EGFR inhibitor gefitinib, a reversibly drug-tolerant persister phenotype was reported to be dependent on JARID1A (KDM5A), a Jumonji histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4) [32].